

**Supplementary Table S2.** Differential expression of hPG, ANXA2 and the CD163/HLA-DR ratio between the primary tumors (T) or the lymph node metastases (LN) and the patients' non-tumoral gastric mucosa (non-tumoral) or healthy controls (healthy)

	p-value
hPG (T) vs. hPG (non-tumoral)	.344
hPG (T) vs. hPG (healthy)	<.001
hPG (non-tumoral) vs. hPG (healthy)	<.001
hPG (LN) vs. hPG (non-tumoral)	.975
hPG (LN) vs. hPG (healthy)	<.001
ANXA2 (T) vs. ANXA2 (non-tumoral)	<.001
ANXA2 (T) vs. ANXA2 (healthy)	<.001
ANXA2 (non-tumoral) vs. ANXA2 (healthy)	.024
ANXA2 (LN) vs. ANXA2 (non-tumoral)	.001
ANXA2 (LN) vs. ANXA2 (healthy)	<.001
CD163/HLA-DR (T) vs. CD163/HLA-DR (non-tumoral)	<.001
CD163/HLA-DR (T) vs. CD163/HLA-DR (healthy)	<.001
CD163/HLA-DR (non-tumoral) vs. CD163/HLA-DR (healthy)	.108
CD163/HLA-DR (LN) vs. CD163/HLA-DR (non-tumoral)	<.001
CD163/HLA-DR (LN) vs. CD163/HLA-DR (healthy)	<.001

hPG, progastrin; ANXA2, annexin A2; HLA-DR, human leukocyte antigen-DR.